Who is sponsoring NCT05776797?

NCT05776797 is sponsored by University Hospital Ostrava.

What drugs are being tested in NCT05776797?

Interventions in NCT05776797: Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT), Optimal medication treatment in patients with cardiac resynchronization therapy (CRT).

What condition does NCT05776797 study?

NCT05776797 studies Recurrent Atrial Fibrillation, Persistent Atrial Fibrillation.

Is NCT05776797 still recruiting?

NCT05776797 is currently recruiting now. Last updated 8 June 2023.

Last reviewed 2023-06-08 · How we verify

NCT05776797: AMPER-AF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation

Recruiting now NA Last updated 8 June 2023

What this trial tests

NA trial testing Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT) in Recurrent Atrial Fibrillation in 480 participants. Currently enrolling.

Timeline

1 April 2023

Primary endpoint
31 December 2028

31 March 2029

Quick facts

Lead sponsor	University Hospital Ostrava
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	480
Start date	1 April 2023
Primary completion	31 December 2028
Estimated completion	31 March 2029
Sites	9 locations across Czechia

Drugs / interventions tested

Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)
Optimal medication treatment in patients with cardiac resynchronization therapy (CRT) — full drug profile →

Conditions studied

Recurrent Atrial Fibrillation — all drugs for Recurrent Atrial Fibrillation →
Persistent Atrial Fibrillation — all drugs for Persistent Atrial Fibrillation →

Sponsor

University Hospital Ostrava

Who can join

Adults 18 to 85, any sex, with Recurrent Atrial Fibrillation or Persistent Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study comparing atrioventricular junction ablation (AVJA) versus continued optimum medical rate control in patients with cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) with suboptimal heart rate control on optimum medication.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital Ostrava trials

Trials by the same sponsor.

NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
NCT07041086 — Prehospital ECPR in Moravia Silesia Region · recruiting
NCT07009652 — Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian · recruiting
NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05776797 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Ostrava
Last refreshed: 8 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05776797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing